{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:18:03Z","timestamp":1782908283487,"version":"3.54.5"},"reference-count":63,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T00:00:00Z","timestamp":1195603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Calcimimetics reduce serum levels of parathyroid hormone (PTH) and calcium, with a leftward shift in the set\u2010point for calcium\u2010regulated PTH secretion. The aim of this publication is to review the data available for calcimimetics in primary, secondary and tertiary hyperparathyroidism (HPT).<\/jats:p><jats:p>Parathyroidectomy (PTX) is currently the only curative treatment for primary HPT, and recommended for patients with moderate\u2010to\u2010severe disease, as defined by a 2002 National Institute's of Health summary statement. In general, patients with primary HPT not meeting these surgical criteria, as well as those with contraindication or refusal for surgery, are monitored for signs and symptoms of primary HPT. There are currently no non\u2010surgical therapies approved for use in primary HPT, although bisphosphonates are used in some patients, in an effort to control serum calcium levels. Calcimimetics decrease PTH and calcium levels and are a potential alternative for patients contraindicated for PTX, or who have failed previous PTX and have recurrent primary HPT.<\/jats:p><jats:p>Secondary HPT develops early in chronic kidney disease and is present virtually in all patients with end\u2010stage renal disease (ESRD). Secondary HPT is a progressive disease and is associated with several systemic complications, including renal osteodystrophy, soft tissue and vascular calcifications, and adverse cardiovascular outcomes. In ESRD patients, calcimimetics were shown to simultaneously reduce PTH, calcium, phosphate and calcium\u00a0\u00d7\u00a0phosphate product. In addition, observational analyses of use of calcimimetics in the ESRD population have shown a reduction of important clinical outcomes.<\/jats:p><jats:p>In renal allograft recipients with tertiary HPT and hypercalcaemia, calcimimetics are a promising treatment option to control the parameters of calcium phosphate metabolism and may be a valid alternative to PTX.<\/jats:p><jats:p>Based on its unique mechanism of action, the calcimimetic cinacalcet may play a role in the medical treatment of primary and tertiary forms of HPT, in addition to the registered indication for the treatment of secondary HPT.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2007.01874.x","type":"journal-article","created":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T19:48:16Z","timestamp":1195674496000},"page":"915-922","source":"Crossref","is-referenced-by-count":66,"title":["The role of calcimimetics in the treatment of hyperparathyroidism"],"prefix":"10.1111","volume":"37","author":[{"given":"R. P.","family":"W\u00fcthrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,11,21]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:10:2:97"},{"key":"e_1_2_4_3_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-3565(24)34924-9","article-title":"NPS R\u2010568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium","volume":"290","author":"Fox J","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119851"},{"key":"e_1_2_4_5_2","unstructured":"Prescribing information of Mimpara\u00ae EMEA.http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/mimpara\/H\u2010570\u2010PI\u2010en.pdf(accessed 31 May 2007)."},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186281"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.203"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90330-9"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.180.45"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026570518919"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00386.x"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000141016.20133.33"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67103.x"},{"issue":"2","key":"e_1_2_4_14_2","first-page":"S25","article-title":"Epidemiology of primary hyperparathyroidism","volume":"6","author":"Melton LJ 3rd","year":"1991","journal-title":"J Bone Miner Res"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1988.tb01163.x"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110570"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650040302"},{"issue":"2","key":"e_1_2_4_18_2","first-page":"S85","article-title":"Characterization and evaluation of asymptomatic primary hyperparathyroidism","volume":"6","author":"Bilezikian JP","year":"1991","journal-title":"J Bone Miner Res"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90346-F"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021370"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411701"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp032200"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01306-2"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-4-831"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606053142304"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020667"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030908"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021597"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0842"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.4.4726"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073945"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2006.01183.x"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004100885"},{"key":"e_1_2_4_34_2","first-page":"70","article-title":"Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis","volume":"46","author":"Koskimies O","year":"1996","journal-title":"Clin Nephrol"},{"key":"e_1_2_4_35_2","first-page":"E961","article-title":"Calcitriol therapy and calcium\u2010regulated PTH secretion in patients with secondary hyperparathyroidism","volume":"267","author":"Ramirez JA","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00450.x"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh834"},{"key":"e_1_2_4_38_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman WG","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01665.x"},{"key":"e_1_2_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"e_1_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2006.10.004"},{"key":"e_1_2_4_43_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2006.10.010"},{"key":"e_1_2_4_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2006.10.005"},{"key":"e_1_2_4_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_4_46_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004060512"},{"key":"e_1_2_4_47_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","article-title":"Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats","volume":"11","author":"Chin J","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_4_48_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005040342"},{"key":"e_1_2_4_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67139.x"},{"key":"e_1_2_4_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"e_1_2_4_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh829"},{"key":"e_1_2_4_52_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"e_1_2_4_53_2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO (4), Ca \u00d7 PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh SK","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_4_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027843"},{"key":"e_1_2_4_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199502150-00009"},{"key":"e_1_2_4_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.suppl_3.94"},{"key":"e_1_2_4_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00938.x"},{"key":"e_1_2_4_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh128"},{"key":"e_1_2_4_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh925"},{"key":"e_1_2_4_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl560"},{"key":"e_1_2_4_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh924"},{"key":"e_1_2_4_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01475.x"},{"key":"e_1_2_4_63_2","doi-asserted-by":"crossref","unstructured":"KruseAE EisenbergerU FreyFJ MohauptMG.Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism.Nephrol Dial Transplant2007.","DOI":"10.1093\/ndt\/gfm270"},{"key":"e_1_2_4_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.2007.04121_8.x"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2007.01874.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2007.01874.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T19:34:33Z","timestamp":1737574473000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2007.01874.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,21]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1365-2362.2007.01874.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01874.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,21]]}}}